Regression of left ventricular hypertrophy with moexipril, an angiotensin-converting enzyme inhibitor, in hypertensive patients

American Journal of Therapeutics

Volumn 12, Issue 1, 2005, Pages 3-8

  Sayegh, Fady ^a   Topouchian, Jirar ^a   Hlawaty, Marta ^a   Olzewska, Maria ^a   Asmar, Roland ^a  

^a L'Institut CardioVasculaire   (France)

Author keywords

Angiotensin converting enzyme inhibitor; Echocardiography; Hypertension; Left ventricular hypertrophy; Moexipril

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MOEXIPRIL;

ACUTE CHOLECYSTITIS; ADULT; AGED; ALLERGY; ANXIETY DISORDER; ARTICLE; BLOOD PRESSURE REGULATION; BODY SURFACE; BRONCHITIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COUGHING; ECHOCARDIOGRAPHY; ESSENTIAL HYPERTENSION; FEMALE; FLU LIKE SYNDROME; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; ISCHIALGIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHARYNGITIS; PRIORITY JOURNAL; REMISSION; RISK FACTOR; SINGLE BLIND PROCEDURE; TONGUE CARCINOMA;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; TETRAHYDROISOQUINOLINES; TREATMENT OUTCOME;

EID: 17144372987     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045391-200501000-00002     Document Type: Article

References (27)

1. Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322:1561-1566.
2. Dahlöf B. Structural cardiovascular changes in essential hypertension. Studies on the effects of antihypertensive therapy. Blood Press. 1992;1(suppl 6):1-75.
3. The Sixth Report of the Joint National Committee on Prevention. Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Arch Intern Med. 1997;157:2413-2446.
4. World Health Organization. 1999 International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens. 1999;17:151-183.
5. Lavie CJ, Ventura HO, Messerli FH. Regression of increased left ventricular mass by antihypertensives. Drugs. 1991;42:945-996.
6. Dahlöf B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A meta-analysis of 109 treatment studies. Am J Hypertens. 1992;5:95-110.
7. Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA. 1996;275:1507-1513.
8. Brogden RN, Wiseman LR. Moexipril. A review of its use in the management of essential hypertension. Drugs. 1998; 55:845-860.
9. Drayer JIM, Stimpel M, Fox A, et al. The antihypertensive properties of the angiotensin-converting enzyme inhibitor moexipril given alone or in combination with a low dose of a diuretic. Am J Ther. 1995;2:525-531.
10. White WB, Fox AAL, Stimpel M. Long-term efficacy and safety of moexipril in the treatment of hypertension. J Hum Hypertens. 1994;8:917-921.
11. Ganau A, Devereux RB, Roman MJ, et al. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol. 1992;19:1550-1558.
12. Devereux RB, Pini R, Aurigemma GP, et al. Measurement of left ventricular mass: methodology and expertise. J Hypertens. 1997;15:801-809.
13. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation. 1977;55:613-618.
14. Gottdiener JS, Livengood SV, Meyer PS, et al. Should echocardiography be performed to assess effects of antihypertensive therapy? Test-retest reliability of echocardiography for measurement of left ventricular mass and function. J Am Coll Cardiol. 1995;25:424-430.
15. Schiller NB, Shah PM, Crawford M, et al. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms: recommendations for quantitation of the left ventricle by two-dimensional echocardiography. J Am Soc Echocardiography. 1989;2:358-367.
16. Lorell BH, Carabello BA. Left ventricular hypertrophy. Pathogenesis, detection, and prognosis. Circulation. 2000; 102:470-479.
17. Wachtell K, Bella JN, Liebson PR, et al. Impact of different partition values on prevalences of left ventricular hypertrophy and concentric geometry in a large hypertensive population. The LIFE study. Hypertension. 2000;35:6-12.
18. Gosse P, Sheridan DJ, Zannad F, et al. on behalf of the LIVE investigators. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: the LIVE study. J Hypertens. 2000;18:1465-1475.
19. de Simone G, Daniels SR, Devereux RB, et al. Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and impact of overweight. J Am Coll Cardiol. 1992;20:1251-1260.
20. de Simone G, Devereux RB, Daniels SR, et al. Effect of growth on variability of left ventricular mass: assessment of allometric signals in adults and children and their capacity to predict cardiovascular risk. J Am Coll Cardiol. 1995;25:1056-1062.
21. Franz IW, Ketelhut R, Behr U, et al. Long-term studies on regression of left ventricular hypertrophy. J Cardiovasc Pharmacol. 1991;17(suppl 2):S87-S93.
22. Leonetti G, Fogari R, Mazzola C, et al. Effects of blood pressure reduction with trandolapril and enalapril on left ventricular hypertrophy and exercise tolerance. J Hypertens. 1993;11(suppl 5):S356-S357.
23. De Luca N, Rosiello G, Lamenza F, et al. Reversal of cardiac and large artery structural abnormalities induced by long-term antihypertensive treatment with trandolapril. Am J Cardiol. 1992;70:52D-59D.
24. Levy D, Anderson KM, Savage DD, et al. Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. Ann Intern Med. 1988;108:7-13.
25. Cruickshank JM, Lewis J, Moore V, et al. Reversibility of left ventricular hypertrophy by differing types of antihypertensive therapy. J Hum Hypertens. 1992;6:85-90.
26. Stimpel M, Bonn R, Koch B, et al. Pharmacology and clinical use of the new ACE-inhibitor moexipril. Cardiovasc Drug Rev. 1995;13:211-229.
27. Fogari R, Zoppi A, Mugellini A, et al. Effects of lisinoprils vs hydralazine on left ventricular hypertrophy and ambulatory blood pressure monitoring in essential hypertension. Eur Heart J. 1995;16:1120-1125.